Comparison of once- and twice-daily clarithromycin in the treatment of adults with severe acute lower respiratory tract infections

Clinical Therapeutics

Volumn 23, Issue 12, 2001, Pages 1958-1968

  Allin, Dennis ^a   James, Ian ^a   Zachariah, Jollye ^a   Carr, William ^a   Cullen, Stephen ^b   Middleton, Alan ^a   Newson, Penny ^c   Lytle, Thomas ^c   Coles, Stephen ^c  

^a Gresford Medical Centre ^*

^b Gresford Medical Centre   (United Kingdom)

^c ABBOTT LABORATORIES   (United Kingdom)

Author keywords

Acute severe lower respiratory tract infections; Clarithromycin once daily; Clarithromycin twice daily

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN;

ACUTE DISEASE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDLINE; MULTICENTER STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; TASTE DISORDER; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0035690612     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80149-1     Document Type: Article

References (21)

1. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics
2. Comparison of macrolide antibiotics
3. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans
4. In vitro activity of clarithromycin and its 14-hydroxy metabolite against 203 strains of Haemophilus influenzae
5. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests
6. Clarithromycin 250 mg b.i.d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis
7. Efficacy and tolerability of clarithromycin versus azithromycin in the short-course treatment of acute bronchitis
8. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis
9. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis
10. Pharmacokinetics and safety of a once-daily clarithromycin formulation
11. A report of the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis
12. BTS guidelines for the management of chronic obstructive pulmonary disease
13. EuroQol: The current state of play
14. Clarithromycin versus cefaclor in lower respiratory tract infections
15. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis
16. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
17. Etiology, susceptibility, and treatment of acute bacterial exacerbation of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus 500 mg b.i.d.
18. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis
19. A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community acquired pneumonia
20. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community